AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
A Phase II Study of AB-16B5 Combined With Docetaxel in Previously Treated Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)
Sponsor: Alethia Biotherapeutics
A PHASE2 clinical study on NSCLC Stage IV, this trial is completed. The trial is conducted by Alethia Biotherapeutics and has accumulated 13 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
May 2025 — Sep 2025 [monthly]
Completed PHASE2
-
Sep 2024 — May 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Apr 2024 — Jul 2024 [monthly]
Completed PHASE2
▶ Show 8 earlier versions
-
Feb 2024 — Apr 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Oct 2023 — Feb 2024 [monthly]
Active Not Recruiting PHASE2
-
Dec 2022 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Dec 2022 [monthly]
Recruiting PHASE2
-
May 2021 — Sep 2022 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2
-
Jul 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE2
-
May 2020 — Jul 2020 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Alethia Biotherapeutics
For direct contact, visit the study record on ClinicalTrials.gov .